November 17, 2021

OWP Pharmaceuticals Announces IND Authorization for the First-Ever Oral Liquid Formulation of Atomoxetine Hydrochloride for the Treatment of Attention Deficit Hyperactivity Disorder

Share this press release:

Document loads below this notification.

Additional Press Releases

May 20, 2024 / Press Release

OWP Pharmaceuticals Announces FDA Filing Acceptance for New Drug Application of SUBVENITE® (lamotrigine) Oral Suspension

August 1, 2023 / Press Release

OWP Pharmaceuticals Announces IND Authorization for First Oral Liquid Formulation of Trazodone for Treatment of MDD

March 14, 2023 / Press Release

Powering Social Enterprise with Profit and Purpose: The Tandem Hybrid by Scott Boyer, Jeremy Gudauskas, and Mike Hamel